Update on bemcentinib’s involvement in potential COVID-19 treatment

7 August 2020 | 12:15 pm
BerGenBio Photo Nils Olav Mevatne
BerGenBio notes the UK Research and Innovation’s (UKRI) decision to cease the grant funding to the University Hospital Southampton NHS Trust for the COVID-19 ACCORD clinical study in which BerGenBio’s bemcentinib was the lead drug candidate to be tested. Subsequently the University Hospital Southampton NHS Trust, who is the study sponsor, has notified all sites […]

Susanna Helgesen leaves Xbrane Biopharma

6 August 2020 | 5:45 am
Xbrane team
Xbrane Biopharma has announced that Susanna Helgesen, CFO of Xbrane Biopahrma, and the company have jointly decided to go their separate ways as there will be a change of the CFO role. Susanna will continue as CFO until a successor is appointed and a date for Susanna’s last day as CFO will be communicated once […]

She receives the FEBS | EMBO Women in Science Award

5 August 2020 | 5:55 am
Elly Tanaka Photo IMP Tkladlez
EMBO and FEBS announced Elly Tanaka of the Research Institute of Molecular Pathology, Vienna BioCenter, Austria, as the recipient of the FEBS | EMBO Women in Science Award 2020. The FEBS | EMBO Women in Science Award recognizes outstanding contributions of female researchers in the life sciences. The recipients are also inspiring role models for […]

Swedish researchers part of a new IMI consortium

4 August 2020 | 5:48 am
Michael Sundström
Researchers at Karolinska Institutet are part of a consortium granted almost 66 million euros by the European Innovative Medicines Initiative (IMI) and other parties. The funds will be used to develop, test and facilitate access to chemical substances and other research tools that could pave the way for new drug targets and treatments of diseases […]

Exact Therapeutics raises 155 million NOK and lists on Oslo Stock Exchange’s Merkur Market

31 July 2020 | 2:50 pm
Exact Therapeutics announces that its shares have been admitted to trading on Oslo Stock Exchange’s Merkur Market under the ticker EXTX-ME with first day of trading 14 July 2020, following the successful completion of a NOK 155 million private placement. Following a bookbuilding period from 4 – 16 June 2020, the company has raised NOK […]

In focus: Medtech innovations in the Nordics

31 July 2020 | 5:00 am
In focus: Medtech innovations in the Nordics
An award winning innovative helmet technology, detecting cancer from breath, self-luminous cancer tissue and hospital health monitoring – examples of recent medtech progress in the Nordic region. Sweden: Innovative helmet technology receives the Polhem Prize Three of the founders of MIPS have been awarded the Polhem Prize.     Since it was founded, MIPS has […]

Financing Q&A: “Make sure your investors can add more than just money!”

30 July 2020 | 5:34 am
Jonas Hansson
Jonas Hansson is a Venture Partner at HealthCap, a European venture capital firm investing exclusively and globally in life sciences. What kind of companies are you and your colleagues focusing your investments on? And what stages?  “We invest in companies/assets in the precision medicine (right medicine for the right patient) space. We like to be […]

Swedish researchers develops material to protect us from pandemics

29 July 2020 | 5:07 am
Martin Andersson
​A new material developed by researchers at Chalmers that can kill bacteria has now shown early promise in de-activation of viruses, including certain coronaviruses. The material is now being evaluated against SARS-CoV-2. Microbe-killing peptides are combined with a nanostructured material ​The novel material, recently presented in a doctoral thesis, has proven to be very effective […]

Rybelsus approved in Japan for the treatment of type 2 diabetes

28 July 2020 | 5:05 am
Mads Krogsgaard Thomsen
Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes. The approval of Rybelsus in Japan is based on results from the PIONEER clinical […]

Careers interview: An appetite for innovation

27 July 2020 | 5:48 am
Caspar Foghsgaard
Business development in a clinical stage vaccine company is constantly changing, intellectually challenging and meaningful job that pushes developments in society. Caspar Foghsgaard is Director of Business Development at the Norwegian vaccine platform company Vaccibody. The company mainly focuses on cancer, but the platform is broadly applicable and the vaccine has shown a favorable safety […]